ACOMPLIA Rimonabant, finally arrives the pill the most waited as far as medecines parala lost from the weight. Rimonabant has been successful in entering the European markets like drug against the obesity. Two years of successful clinical tests finally are preparation the land for the people who look for treatments of the obesity can buy Acomplia (Rimonabant) like a way to control it. Also aid to stop smoking between its positive indirect effect.
GENERAL DESCRIPTION
Rimonabant directly works in the impulse or the yearning to eat more. It works in the system of endocannabinoid, a system that affects the energy balance, the metabolism of the glucose and lipid and corporal weight. When blocking certain receivers in I celebrate, is realised a suppression of the appetite of the patient. Along with a diet of reduced amount of calories and a regime of exercise, aid perceivably to obese patients to reach a loss of weight.
USES
Rimonabant is a drug that takes associate to the diet and exercise for the fat treatment of obese individuals with BMI or equal to 30kg/m2 or patients with BMI or 27 equal to Kg./m2) with the factor (it is) associated from the risk, as type 2 diabetes or dyslipidaemia. It is necessary that the patients take only one tablet from 20mg every morning with the breakfast.
PRECAUTIONS
Contraindications: Rimonabant is due to use with precaution in patients with the following conditions:
How much WEIGHT CAN BE LOST WITH ACOMPLIA?
Placebo-controlled studies have been realised using Rimonabant with more than 6.800 patients and the results were substantial. In the completion of a year and to daily take the pill from Rimonabant 20 mgs, a loss of the weight of 6.5 kilograms were observed like compared like 1.6 kg between those with placebo. The first 9 months were most crucial when the loss of weight (diminution overweight) was reached. Rimonabant also reduced the risk of the recovery of the weight. In an experiment after a year, re-they selected to a group of patients at random. They were observed that the patients who continued in Acomplia 20 mg reached a total losses of the weight of 7.5kg on two years, whereas the patients which they were transferred to placebo had a total losses of the weight of 3.1kg.
IF FORGETFULNESS TO TAKE A DOSE
The forgetfulness of a tablet of Acomplia would not have to cause serious undesirable effects.
INDIRECT EFFECT
Approximated the more common indirect effect undergone by 15,7% of 2500 obese ones or fat patients were nausea, depressive alteration of humor with depressive symptoms, disorders, anxiety and vertigos. Other 3,2% of patients disclosed depressive disorders of smooth or moderate severity. The following table demonstrates all the adverse reactions of the four placebo-controlled clinical studies.
SUGGESTIONS
It fulfills all the appointments with his doctor and the laboratory. His doctor could get to order examinations of laboratory before and during the treatment to verify the answer of his body to the atorvastatina. He does not leave other people take his medicine.
CONSERVATION
It maintains east medicine in his package, closed well and outside the reach of the children. Store it at room temperature and far from the excessive heat and the humidity (not in the bath). It rejects any medicine that is overcome or that no longer is used. Conver with its phamacist about the suitable remainder of medecines.